EconPapers    
Economics at your fingertips  
 

An enterococcal phage protein inhibits type IV restriction enzymes involved in antiphage defense

Nathan P. Bullen, Cydney N. Johnson, Shelby E. Andersen, Garima Arya, Sonia R. Marotta, Yan-Jiun Lee, Peter R. Weigele, John C. Whitney () and Breck A. Duerkop ()
Additional contact information
Nathan P. Bullen: McMaster University
Cydney N. Johnson: School of Medicine
Shelby E. Andersen: School of Medicine
Garima Arya: School of Medicine
Sonia R. Marotta: McMaster University
Yan-Jiun Lee: New England Biolabs
Peter R. Weigele: New England Biolabs
John C. Whitney: McMaster University
Breck A. Duerkop: School of Medicine

Nature Communications, 2024, vol. 15, issue 1, 1-13

Abstract: Abstract The prevalence of multidrug resistant (MDR) bacterial infections continues to rise as the development of antibiotics needed to combat these infections remains stagnant. MDR enterococci are a major contributor to this crisis. A potential therapeutic approach for combating MDR enterococci is bacteriophage (phage) therapy, which uses lytic viruses to infect and kill pathogenic bacteria. While phages that lyse some strains of MDR enterococci have been identified, other strains display high levels of resistance and the mechanisms underlying this resistance are poorly defined. Here, we use a CRISPR interference (CRISPRi) screen to identify a genetic locus found on a mobilizable plasmid from Enterococcus faecalis involved in phage resistance. This locus encodes a putative serine recombinase followed by a Type IV restriction enzyme (TIV-RE) that we show restricts the replication of phage phi47 in vancomycin-resistant E. faecalis. We further find that phi47 evolves to overcome restriction by acquiring a missense mutation in a TIV-RE inhibitor protein. We show that this inhibitor, termed type IV restriction inhibiting factor A (tifA), binds and inactivates diverse TIV-REs. Overall, our findings advance our understanding of phage defense in drug-resistant E. faecalis and provide mechanistic insight into how phages evolve to overcome antiphage defense systems.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-51346-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-51346-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-51346-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-51346-1